로딩 중…
지수 로딩 중…
제넥신
095700· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩2,760-4.33%
2026-06-19
Price Chart
제넥신-42.74%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 125.69B KRW |
| Revenue | 4.67B KRW |
| Net Income | -20.74B KRW |
| Total Assets | 355.17B KRW |
| Net Assets | 246.76B KRW |
| Employees | 89 |
| Value | |
| P/B | 0.51x |
| P/S | 26.92x |
| FCF Yield | -35.26% |
| Profitability | |
| ROE | -8.40% |
| ROA | -5.84% |
| Op. Margin | -785.91% |
| Revenue Growth | 29.80% |
| Financial Health | |
| Debt Ratio | 143.93% |
| Total Debt | 104.23B KRW |
| FCF | -44.32B KRW |
| Cash | 3.85B KRW |
| Current Ratio | 0.30x |
| Performance | |
| 1Y Return | -42.74% |
| 1M Return | -32.68% |
| From 52W High | -63.15% |
| 1Y MDD | -61.13% |
| Trading | |
| Volume | 409,000 shares |
| Foreign Own. | 4.46% |
| Per Share | |
| EPS | -455 KRW |
| BPS | 5,050 KRW |
Company Info
Established in 1999, the company is a biopharmaceutical enterprise listed on the KOSDAQ market since 2009. Through a 2024 merger with EPD Bio Co., Ltd., it secured the bioPROTAC platform technology EPDeg™. The company is developing various therapeutics, including anticancer immunotherapeutics (GX-I7), utilizing hyFc fusion protein and DNA vaccine manufacturing technologies. It aims for technology transfer through joint development and clinical trials with global pharmaceutical companies to secure future growth engines. Genexine is headquartered in Gangseo-gu, Seoul Metropolitan City.